title: [Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer].
abstract: Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer has been performed in our hospital. The purpose of this study was to evaluate the safety and immune response of different dose of RNF43-721 emulsified with Montanide ISA 51 in combination with S-1/CPT-11 chemotherapy. The study design was a dose escalation of peptide (0.5, 1.0, 3.0 mg) with three patients' cohort. Nine patients were enrolled. All patients were treated with peptide subcutaneously every week and two courses with S-1/CPT-11 chemotherapy. Vaccinations were well tolerated without any major adverse events. Immunological reactions are not analyzed yet. We herein report a case who has been evaluated to be long SD with this intervention for para-aortic LN metastasis from sigmoid colon cancer.
authors.affiliation: Dept. of Surgery, Tokyo Women's Medical University, Medical Center East.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yoshimatsu
authors.forename: Hajime
authors.initials: H
authors.lastname: Yokomizo
authors.forename: Gakuji
authors.initials: G
authors.lastname: Osawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Fujimoto
authors.forename: Taisuke
authors.initials: T
authors.lastname: Otani
authors.forename: Takuya
authors.initials: T
authors.lastname: Tsunoda
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Kenji
authors.initials: K
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000276:immunology*; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000276:immunology* / Q000628:therapy*; D003131:Combined Modality Therapy; D004338:Drug Combinations; D015234:HLA-A Antigens / Q000276:immunology; D059871:HLA-A24 Antigen; D006801:Humans; D007167:Immunotherapy; D000077146:Irinotecan; D008297:Male; D010094:Oxonic Acid / Q000627:therapeutic use*; D010455:Peptides / Q000276:immunology*; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
chemical_list: D019496:Cancer Vaccines; D004338:Drug Combinations; D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D010455:Peptides; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin